Table 2.
Final multivariate analysis for cardiovascular death risk among people with type 2 diabetes and a new clinical diagnosis of DN in derivation cohort
| Parameters | Coefficients | 95% CI |
| Gender: male vs female | 0.157086 | 0.113221 to 0.200952 |
| (Age/10)3 | 0.000782 | −0.002189 to 0.003752 |
| (Age/10)3×ln(age/10) | 0.000499 | −0.000851 to 0.001849 |
| (Body mass index/10)3 | 1.057959 | 0.938973 to 1.176945 |
| (Body mass index/10)3×ln(body mass index/10) | −0.831356 | −0.923908 to−0.738804 |
| Systolic blood pressure ≥150 mm Hg | 0.132676 | 0.087332 to 0.178021 |
| Diastolic blood pressure ≥90 mm Hg | 0.022270 | −0.022518 to 0.067057 |
| (Fasting glucose/10)2 | 0.562659 | 0.480369 to 0.644950 |
| (Fasting glucose/10)3 | −0.207944 | −0.246155 to −0.169732 |
| (e(high-density lipoprotein cholesterol)/10)−0.5 | −5.667237 | −6.281152 to −5.053321 |
| (e(high-density lipoprotein cholesterol)/10)−0.5×ln(e(high-density lipoprotein cholesterol)/10) | −1.998909 | −2.190463 to −1.807355 |
| {e[log10(Triglyceride)]}−0.5 | 0.350930 | −0.475933 to 1.177792 |
| {e[log10(Triglyceride)]}−0.5×ln{e[log10(Triglyceride)]} | −0.308807 | −0.692824 to 0.075210 |
| Low-density lipoprotein cholesterol ≥2.60 | 0.322825 | 0.278944 to 0.366706 |
| International normalized ratio ≥0.86 or D-dimer ≥0.15 or fibrinogen ≥3.19 or thrombin time ≥14.8 | 1.929119 | 1.779267 to 2.078971 |
| Prothrombin time activity ≥128 or activated partial thromboplastin time ≥33.56 or prothrombin time ≥9.8 | 1.005904 | 0.852349 to 1.159459 |
| Thyroid-stimulating hormone ≥2.04 or free thyroxine ≥11.93 or free triiodothyronine ≥4.24 | −0.176353 | −0.234195 to −0.118511 |
| Magnesium ≥0.93 or phosphorus ≥1.23 or potassium ≥4.36 or sodium ≥141 | 0.138010 | 0.061919 to 0.214101 |
| HCO3 ≥23.6 or chlorine ≥102.3 or calcium ≥2.23 | −0.545899 | −0.601485 to −0.490313 |
| Total bilirubin ≥7.2 or total protein ≥63.4 | −0.741628 | −0.790879 to −0.692376 |
| Cholinesterase ≥6.85 or alanine transaminase ≥16 or gamma-glutamyl transtransferase ≥23 or alkaline phosphatase ≥74 | −0.278849 | −0.342571 to −0.215127 |
| Direct bilirubin ≥3.4 or globulin ≥25.48 or indirect bilirubin ≥3.7 | 0.385626 | 0.324596 to 0.446655 |
| Urine-specific gravity ≥1.01 or 24 hours total urine protein ≥0.86 or urea ≥7.38 | 1.789318 | 1.605494 to 1.973141 |
| Basophil ≥0.03×109/L or eosinophil granulocyte ≥0.13×109/L or mean corpuscular hemoglobin ≥29.9 or platelet distribution width ≥16.75 or plateletcrit ≥0.169% or monocytes ≥7.5% | −1.364007 | −1.552228 to −1.175786 |
| Lymphocyte ≥26.1% or neutrophil ≥63% or hemoglobin ≥117 | −0.476919 | −0.588630 to −0.365208 |
| Hematocrit ≥0.37 or red blood cell distribution width ≥13.6% or neutrophil ≥4.2×109/L or mean corpuscular hemoglobin concentration ≥329 | −0.228664 | −0.359169 to −0.098159 |
| Lymphocyte ≥1.7×109/L or mean corpuscular volume ≥91 or monocytes×109/L≥0.5 | 0.411002 | 0.346310 to 0.475694 |
| Constant | −4.073395 | −5.295054 to −2.851736 |
DN, diabetic nephropathy.